Yemen FM: Biden's Visit Presents Opportunity to Achieve Consensus on Yemen Crisis

Yemeni Foreign Minister Ahmed Awad bin Mubarak (Asharq Al-Awsat)
Yemeni Foreign Minister Ahmed Awad bin Mubarak (Asharq Al-Awsat)
TT

Yemen FM: Biden's Visit Presents Opportunity to Achieve Consensus on Yemen Crisis

Yemeni Foreign Minister Ahmed Awad bin Mubarak (Asharq Al-Awsat)
Yemeni Foreign Minister Ahmed Awad bin Mubarak (Asharq Al-Awsat)

Yemeni Foreign Minister Ahmed Awad bin Mubarak considered the upcoming visit of US President Joe Biden to Saudi Arabia an opportunity to achieve regional and international consensus that would be reflected in resolving the Yemeni crisis.

“We look at the visit positively, hoping that the US administration will renew its position in support of the stability and security of the region in general and Yemen in particular,” said bin Mubarak.

“The visit constitutes an opportunity to achieve regional-international consensus on the Yemeni issue, in light of the recent developments and the continuation of the coup militias to obstruct the path of the UN truce,” he added.

In an exclusive interview with Asharq Al-Awsat, Mubarak stressed that the only way to ensure stability and security requires stopping Iranian meddling in Yemen.

“To ensure the stability of energy markets in the world, the region must be stable, and here we are talking especially about Yemen,” said bin Mubarak.

“It is not possible to talk about the stability of the region and the world, and the guarantee of the flow of energy and food supplies, in light of the clear Iranian interference and support for the Houthi militias threatening international shipping lanes,” he added.

“We believe that stopping the Iranian regime's interference in Yemen is the only way to establish peace and stability,” asserted bin Mubarak.

He also noted that Yemen doesn’t need more initiatives, but rather needs existing ones to be implemented.

The top Yemeni diplomat also doubted the truce with the militias would last, especially that the Iran-backed group has already failed to fulfill its commitments and chose to escalate on several fronts.

Mubarak described Yemen-US relations as “strategic.”

Yemen’s ties with Washington do not stop at combating terrorism only, but also go beyond that to support building Yemeni institutions, providing humanitarian aid, and supporting the Yemeni people in various crises and stages, affirmed the foreign minister.



Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation
TT

Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation

Dr. Mehmood Khan, CEO of the Hevolution Foundation, the largest philanthropy organization funding aging medicine in the world, expressed that receiving Saudi citizenship will boost his scientific and practical capabilities.
He said this new status will help him advance his research, especially in addressing aging.
This comes as part of a recent royal decree granting Saudi citizenship to several notable scholars, doctors, researchers, and innovators.
“Our Chairman, his Royal Highness (Crown Prince Mohammed bin Salman), has very high expectations of our work and the impact we need to do; We were created in part because of his vision,” Khan told Asharq Al-Awsat.
“Living up to the expectations and challenges we get faced with is itself exciting, but it is challenging,” revealed Khan, affirming that Hevolution’s team is “up to that task.”
Khan, who has experience in both corporate and medical fields, told Asharq Al-Awsat that his work across academic, public, and private sectors has been a continuous learning process, with each area enhancing the others.
According to the CEO, these industries are interconnected, and combining their strengths often leads to the best solutions.
This insight inspired the Hevolution initiative, which brings together the scientific community, NGOs, pharmaceutical companies, policymakers, academia, biotech firms, CEOs, and others to promote healthy aging.
Khan highlighted the value of integrating insights from different sectors.
Academia provides detailed research, the public sector offers insights on population health and regulations, and the corporate world brings innovation and efficiency, explained Khan, adding that by merging these perspectives, the world can tackle complex health challenges more effectively.
“We’ve been working through, and are now investing, funding and partnering with over 200 scientists around the world, and over 150 different university labs,” said Khan.
Hevolution uses this integrated approach to advance healthy aging.
This initiative embodies my passion for addressing major challenges and offers a significant opportunity to make a global impact.
Khan talked about the first $400 million commitment Hevolution made in the last 23 months, calling it “unprecedented.”
“There has never been a non-profit organization in the world that has gone from not existing to now becoming the largest philanthropy funding aging biology and medicine in the world,” affirmed Khan.
Khan stressed that work at Hevolution not only pushes scientific boundaries but also promotes cross-sector collaboration to improve global health outcomes.
Since Khan’s early days in medical school, he’s been deeply interested in nutrition and population health, which was an unconventional focus back then. This journey set the foundation for his later work in community health.
Khan’s time as an endocrinology faculty member at the Mayo Clinic was crucial. He led programs on diabetes, endocrine diseases, metabolism, and nutrition, which strengthened his expertise in designing disease prevention systems.
In the private sector, Khan took on a key role at Takeda Pharmaceutical as the global head of R&D, which shaped his approach to innovative healthcare solutions.
At PepsiCo, as Chief Scientific Officer, he learned crucial principles of scale, impact, transformation, and tackling global challenges.
As CEO of Hevolution, Khan uses all his professional experience to advance the foundation’s mission of developing health sciences to address age-related diseases.
Khan serves on the boards of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority (RDIA).
He is the CEO of Life Biosciences, a member of Saudi Arabia’s biotechnology strategy committee, and the chair of the advanced technology visiting committee at the US National Institute of Standards and Technology (NIST).
Khan told Asharq Al-Awsat that he feels honored to have recently become a Saudi citizen by royal decree, while also holding dual US and UK citizenship. This helps him lead Hevolution effectively and work closely with international partners.
Khan commented on his recent Saudi citizenship, saying that in addition to feeling honored to receive Saudi citizenship by royal decree, alongside other distinguished individuals, this recognition is a great privilege.
Being a Saudi citizen, as per Khan, is a significant milestone and acknowledges the progress in his work in aging science and global health. It also strengthens Khan’s commitment to the work at Hevolution.
Khan noted that this new status enhances his ability to build relationships and collaborate within the Kingdom and internationally. It offers a deeper connection with the local community and better opportunities to engage with policymakers and leaders.
He also said that this recognition boosts Hevolution’s global presence and credibility, making the foundation’s collaborations with international scientists and business leaders stronger. It positions Hevolution as a key player in addressing age-related diseases.
Khan emphasized that this honor reflects the hard work and innovation of Hevolution’s entire team.
The CEO said that it was collective efforts that have made this achievement possible.
Khan also said he is excited to engage more deeply with the scientific and medical community in the Kingdom, adding that his new citizenship helps him contribute to Vision 2030 and the national biotechnology strategy, promoting innovation and attracting top global talent.